Hening Lin to Drug Screening Assays, Antitumor
This is a "connection" page, showing publications Hening Lin has written about Drug Screening Assays, Antitumor.
Connection Strength
0.545
-
Pharmacological Advantage of SIRT2-Selective versus pan-SIRT1-3 Inhibitors. ACS Chem Biol. 2021 07 16; 16(7):1266-1275.
Score: 0.171
-
Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model. J Med Chem. 2019 04 25; 62(8):4131-4141.
Score: 0.147
-
Direct Comparison of SIRT2 Inhibitors: Potency, Specificity, Activity-Dependent Inhibition, and On-Target Anticancer Activities. ChemMedChem. 2018 09 19; 13(18):1890-1894.
Score: 0.140
-
Indirubin Derivatives as Dual Inhibitors Targeting Cyclin-Dependent Kinase and Histone Deacetylase for Treating Cancer. J Med Chem. 2021 10 28; 64(20):15280-15296.
Score: 0.044
-
Cysteine derivatives as acetyl lysine mimics to inhibit zinc-dependent histone deacetylases for treating cancer. Eur J Med Chem. 2021 Dec 05; 225:113799.
Score: 0.043